Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2041

Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.

Patents
2,000

Quick answer

2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 11019810

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. DE 102019218589

    Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen

    BAYER AG [DE] · Granted Wed Jun 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue May 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. DE 102019218587

    Kontrastmittelbasierte Gefäßdarstellung

    BAYER AG [DE] · Granted Wed Jun 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue May 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 2021163596

    IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Thu Jun 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed May 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11026931

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11028412

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11028144

    Soluble glycoprotein V for treating thrombotic diseases

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11028362

    Decellularized human amniotic membrane for cell delivery, cell culture and inflammation prevention

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11028129

    Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11028162

    Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11026947

    ALK2 inhibitors and methods for inhibiting BMP signaling

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11026988

    Traditional Chinese medicine composition and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11026920

    Use of NK-1 receptor antagonist serlopitant in pruritus

    Vyne Therapeutics Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11026997

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11026889

    Polymeric drug delivery systems for treatment of disease

    The Board of Regents of the University of Texas System · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11027008

    Recombinant mumps virus vaccine

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11028050

    Salts and polymorphs of a PDE4 inhibitor

    Tetra Discovery Partners · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11028444

    Survival predictor for diffuse large B cell lymphoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11028161

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11028369

    Induced extended pluripotent stem cells, method of making and using

    BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11028388

    CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa

    Editas Medicine, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11028160

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11028392

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11028152

    Single domain antibodies to Chikungunya virus

    The Government of the United States of America, as represented by the Secretary of the Navy · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11028126

    Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11028128

    Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11028153

    Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11028085

    Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists

    Nimbus Saturn, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11028083

    Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

    The Board of Regents of the University of Texas System · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11028079

    Small molecule BET bromodomain inhibitors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11028061

    Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11028068

    Somatostatin modulators and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11028048

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11027071

    Intradermal jet injection electroporation device

    Inovio Pharmaceuticals, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11027007

    Recombinant metapneumovirus F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11027001

    Therapeutic cancer vaccines derived from a novel dendritic cell line

    DCPRIME B.V. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11027000

    AADC polynucleotides for the treatment of Parkinson's disease

    VOYAGER THERAPEUTICS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11026998

    Shaped mass composition comprising exenatide

    Rani Therapeutics, LLC · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11026974

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11026969

    High affinity T cell receptors and uses thereof

    Adaptive Biotechnologies Corporation · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11026960

    Esters of 2-deoxy-monosaccharides with anti proliferative activity

    The Board of Regents of the University of Texas System · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11026978

    Compositions and methods for treating multiple sclerosis and related disorders

    Finch Therapeutics Holdings LLC · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11026905

    STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11026898

    Eutectic formulations of cyclobenzaprine hydrochloride

    TONIX PHARMA LIMITED · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11026939

    High dosage valbenazine formulation and compositions, methods, and kits related thereto

    Neurocrine Biosciences, Inc. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11028120

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. EP 3831384

    VERWENDUNG VON MASITINIB ZUR BEHANDLUNG VON EOSINOPHILEM ASTHMA

    AB SCIENCE [FR] · Granted Wed Jun 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Jun 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11033626

    Progesterone formulations having a desirable pk profile

    Compass Therapeutics LLC · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2041?

2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.